Jessica Hopfield
CIK 1648715 · last filed 2026-06-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PODD price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
100 NAGOG PARK
ACTON, MA 01720
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EDIT | Director | 67,700 | $2.49 | $168.6K | $1.01M | 13 | 2026-06-22 |
| PODD | Director | 29,355 | $148.12 | $4.35M | -$3.18M | 16 | 2026-05-21 |
| MRVI | Director | 199,907 | $7.07 | $1.41M | $1.35M | 6 | 2025-06-18 |
| Bruker Cellular Analysis, Inc. (CELL) Delisted | Director | 105,207 | $1.00 | $105.0K | $0 | 2 | 2023-10-03 |
| Bruker Cellular Analysis, Inc. (BLI) Delisted | Director | 109,237 | $1.20 | $131.1K | $502.4K | 4 | 2022-08-01 |
| Radius Health, Inc. (RDUS) Delisted | Director | 18,300 | $30.00 | $549.0K | $246.2K | 3 | 2020-02-24 |
Recent Filings · Page 2 of 5
48 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-09-11 | PODD | Notice (144) | −7,628 | -$1.72M | EDGAR |
| 2024-06-03 | EDIT | Grant (A) | — | $0 | EDGAR |
| 2024-05-24 | MRVI | Grant (A) | +20,645 | $222.6K | EDGAR |
| 2024-05-23 | PODD | Grant (A) | +1,380 | $0 | EDGAR |
| 2024-05-14 | EDIT | Buy (P) | +45,000 | $253.9K | EDGAR |
| 2023-10-03 | Bruker Cellular Analysis, Inc. (CELL) Delisted | Mixed | −179,237 | $0 | EDGAR |
| 2023-07-19 | MRVI | Grant (A) | +24,000 | $0 | EDGAR |
| 2023-06-05 | EDIT | Grant (A) | — | $0 | EDGAR |
| 2023-06-01 | Bruker Cellular Analysis, Inc. (CELL) Delisted | Grant (A) | +70,000 | $0 | EDGAR |
| 2023-05-24 | PODD | Grant (A) | +843 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.